A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23)

Cancer Research

Volumn 71, Issue 2, 2011, Pages 339-348

  Morito, Naoki ^a   Yoh, Keigyou ^a   Maeda, Atsuko ^a   Nakano, Takako ^a   Fujita, Akiko ^a   Kusakabe, Manabu ^a   Hamada, Michito ^a   Kudo, Takashi ^a   Yamagata, Kunihiro ^a   Takahashi, Satoru ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA7 INTEGRIN; TRANSCRIPTION FACTOR C MAF;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CELL EXPANSION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; GENE TARGETING; HUMAN; LYMPHOMA CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALS; B-LYMPHOCYTES; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 16; DISEASE MODELS, ANIMAL; HUMANS; HYPERGAMMAGLOBULINEMIA; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-MAF; TRANSLOCATION, GENETIC;

EID: 78751506173     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1057     Document Type: Article

References (46)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
2. Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer 2006;42:1671-83.
3. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996; 88:674-81.
4. Chesi M, Nardini E, Brents LA, Schröck E, Ried T, Kuehl WM, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260-4.
5. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025-34.
6. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998;91:4457-63.
7. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cells 2004;5:191-9.
8. Nishizawa M, Kataoka K, Goto N, Fujiwara KT, Kawai S. v-maf, a viral oncogene that encodes a "leucine zipper" motif. Proc Natl Acad Sci U S A 1989;86:7711-5.
9. Kataoka K, Noda M, Nishizawa M. Maf nuclear oncoprotein recognizes sequences related to an AP-1 site and form heterodimers with both Fos and Jun. Mol Cell Biol 1994;14:700-12.
10. Swaroop A, Xu J, Pawar H, Jackson A, Skolnick C, Agarwal N. A conserved retina-specific gene encodes a basic motif/leucine zipper domain. Proc Natl Acad Sci USA 1992;89:266-70.
11. Ogino H, Yasuda K, et al. Induction of lens differentiation by activation of a bZIP transcription factor, L-Maf. Science 1998;280:115-8.
12. Kajihara M, Kawauchi S, Kobayashi M, Ogino H, Takahashi S, Yasuda K. Isolation, characterization, and expression analysis of zebrafish large Mafs. J Biochem 2001;129:139-46.
13. Ho IC, Hodge MR, Rooney JW, Glimcher LH. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996;85:973-83.
14. Kawauchi S, Takahashi S, Nakajima O, Ogino H, Morita M, Nishizawa M, et al. Regulation of lens fiber cell differentiation by transcription factor c-Maf. J Biol Chem 1999;274:19254-60.
15. Kim JI, Li T, Ho IC, Grusby MJ, Glimcher LH. Requirement for the c-Maf transcription factor in crystallin gene regulation and lens development. Proc Natl Acad Sci U S A 1999;96:3781-5.
16. Ring BZ, Cordes SP, Overbeek PA, Barsh GS. Regulation of mouse lens fiber cell development and differentiation by the Maf gene. Development 2000;127:307-17.
17. Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y, et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res 2006;66:812-9.
18. Murakami YI, Yatabe Y, Sakaguchi T, Sasaki E, Yamashita Y, Morito N, et al. c-Maf expression in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2007;31:1695-702.
19. Nagaoka H, Takahashi Y, Hayashi R, Nakamura T, Ishii K, Matsuda J, et al. Ras mediates effector pathways responsible for pre-B cell survival, which is essential for the developmental progression to the late pre-B cell stage. J Exp Med 2000;192:171-82.
20. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006;103:7024-9.
21. Morito N, Yoh K, Hirayama A, Itoh K, Nose M, Koyama A, et al. Nrf2 deficiency improves autoimmune nephritis caused by the fas mutation lpr. Kidney Int 2004;65:1703-13.
22. Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol 2006;17:2533-45.
23. Eychène A, Rocques N, Pouponnot C. A new MAFia in cancer. Nat Rev Cancer 2008;8:683-93.
24. Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc fingercontaining protein that can drive the maturation of B lymphocytes into immunoglobulin- secreting cells. Cell 1994;77:297-306.
25. Schliephake DE, Schimpl A. Blimp-1 overcomes the block in IgM secretion in lipopolysaccharide/anti-muF(ab')2-co-stimulated B lymphocytes. Eur J Immunol 1996;26:268-71.
26. Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol 2000;1:526-32.
27. Reimold AM, Ponath PD, Li YS, Hardy RR, David CS, Strominger JL, et al. Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1. J Exp Med 1996;183:393-401.
28. Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cells 2007;11:349-60.
29. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi- Tsuda E, Gravallese EM, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300-7.
30. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature 2008;454:226-31.
31. Robbiani DF, Colon K, Ely S, Chesi M, Bergsagel PL. Osteopontin dysregulation and lytic bone lesions in multiple myeloma. Hematol Oncol 2007;25:16-20.
32. Kataoka K, Nishizawa M, Kawai S. Structure-function analysis of the maf oncogene product, a member of the b-Zip protein family. J. Virol 1993;67:2133-41.
33. Nishizawa M, Kataoka K, Vogt PK. MafA has strong cell transforming ability but is a weak transactivator. Oncogene 2003;22:7882-90.
34. Pouponnot C, Sii-Felice K, Hmitou I, Rocques N, Lecoin L, Druillennec S, et al. Cell context reveals a dual role for Maf in oncogenesis. Oncogene 2006;25:1299-310.
35. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007;20:571-96.
36. Hanamura I, Iida S, Akano Y, Hayami Y, Kato M, Miura K, et al. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20) (q32;q11) chromosomal translocations. Jpn J Cancer Res 2001; 92:638-44.
37. Strasser A, Pascual V. Pathophysiology of Waldenströom's macroglobulinemia. Haematologica 2010;95:359-64.
38. Cohen SM, Petryk M, Varma M, Kozuch PS, Ames ED, Grossbard ML. Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue. Oncologist 2006;11:1100-17.
39. Qi CF, Zhou JX, Lee CH, Naghashfar Z, Xiang S, Kovalchuk AL, et al. Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. Cancer Res 2007;67:2439-47.
40. Qi CF, Shin DM, Li Z, Naghashfar Z, Xiang S, Kovalchuk AL, et al. Anaplastic plasmacytomas: relationships to normal memory B cells and plasma cell neoplasms of immunodeficient and autoimmune mice. J Pathol 2010;221:106-16.
41. Ishikawa F, Saito Y, Shultz LD. Modeling human leukemia using immune-compromised mice. In: Li S, editor. Mouse Models of Human Blood Cancers. New York: Springer; 2008. p.121-9.
42. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374:324-39.
43. Rosenbaum H, Harris AW, Bath ML, McNeall J, Webb E, Adams JM, et al. An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J 1990;9:897-905.
44. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A 1992;89:232-5.
45. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990;348:331-3.
46. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cells 2008;13:167-80.